2-oxysubunit-1H-quinoline-4-formic acid derivative as well as preparation method and application thereof
By developing 2-oxygen subunit-1H-quinoline-4-formic acid derivatives, the problem of poor efficacy of existing NQO1 inhibitors in tumor cells is solved, and efficient inhibition of NQO1 enzyme and anti-tumor drugs are achieved. The synergistic effect of medication has improved the therapeutic effect on pancreatic cancer and non-small cell lung cancer.
Patent Information
- Application Number
- CN202411076950.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-07
AI Technical Summary
The role of existing NQO1 inhibitors such as dicoumarin in tumor cells is affected by widespread protein binding and confounding effects, resulting in poor efficacy and side effects. It is necessary to develop more effective NQO1 inhibitors to improve the anti-tumor treatment effect.
A 2-oxygen subunit-1H-quinoline-4-formic acid derivative was developed to bind to NQO1 enzyme through a specific chemical structure, effectively inhibit its activity, and used in combination with anti-tumor drugs to improve therapeutic effect.
This compound can significantly inhibit NQO1 enzyme activity, reduce the dosage of anti-tumor drugs, reduce side effects, improve the therapeutic effect on pancreatic cancer and non-small cell lung cancer, and enhance synergistic effects with existing drugs.
Smart Images

Figure CN118994003A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an NQO1 inhibitor, in particular to a 2-oxyylidene-1H-quinoline-4-carboxylic acid derivative and a preparation method and application thereof, belonging to the field of compound medicine. Background Art
[0002] NAD(P)H:quinone oxidoreductase 1 (NQO1) is a homodimeric flavin enzyme, also known as D-lipoamide dehydrogenase (DT-diaphorase). It is a two-electron oxidoreductase widely present in cells. It is mainly distributed in the cytoplasm (>90%) and the nucleus. It uses flavin adenine dinucleotide (FAD) as a cofactor and coenzyme NAD(P)H as an electron donor. It can reduce quinones to corresponding hydroquinones through a one-step two-electron transfer process. The process of NQO1 catalyzing the two-electron reduction of substrates is completed through a "ping-pong mechanism". As a phase II metabolic enzyme, NQO1 is not abundant in normal human tissues. However, under oxidative stress conditions, NQO1 will be transcribed and expressed under the control of related signal pathways to exert its physiological functions. The main functions include: 1) two-electron reduction of quinone and its derivatives to prevent them from being reduced and activated by single-electron reductase to produce semiquinone free radicals and ROS, thereby preventing quinone substances from directly causing harm to the human body; 2) as a component of the body's antioxidant system, it directly removes superoxide anions through NAD(P)H-dependent reduction reactions; 3) maintains the reduced state of endogenous fat-soluble antioxidants α-tocopherol and ubiquinone to maintain their activity; and stabilizes the tumor suppressor p53 and other proteins through protein-protein interactions.
[0003] Studies have shown that the expression of NQO1 enzyme is upregulated in many solid tumors, and the expression level in more than 80% of human pancreatic cancer is 100 times that of normal tissues. In addition to lung cancer and pancreatic cancer, the expression level of NQO1 in other solid tumors including breast cancer, prostate cancer, and colorectal cancer is much higher than that in normal tissues. The promotion of NQO1 enzyme on tumor occurrence and development and its high expression in tumor tissues indicate that this protein is a selective anti-tumor therapeutic target. Studies have reported that overexpression of NQO1 induced by transcription factor NRF2 may lead to chemotherapy failure, which may be an adaptive response of the body to oxidative stress and cytotoxicity and provide defense for cancer cells. Therefore, inhibiting the NQO1 enzyme will make selective anticancer treatment of chemotherapy failure caused by the detoxification catalyzed by NQO1 possible. In addition, inhibiting the expression of NQO1 enzyme will cause an increase in ROS in tumor cells, increase their risk of anoikis and reduce the invasiveness of tumor cells, and explore new therapeutic directions for cancer treatment. At the same time, NQO1 enzyme inhibitors can also provide favorable assistance for in-depth research on the pharmacological functions of NQO1 enzymes. At present, some compounds are known to competitively inhibit the activity of NQO1 by binding to NAD(P)H, thereby preventing the reduction of FAD, including chrysin, coumarin, curcumin, triazole acridin-6-one, etc., among which the most representative is dicoumarol (DIC). DIC is often used as an NQO1 inhibitor to study the function of NQO1 in cells. However, this drug also has certain defects. The effect of dicoumarol is affected by extensive protein binding and mixed "off-target" effects, such as mitochondrial uncoupling and increased production of intracellular superoxide. Therefore, it is still necessary to develop NQO1 inhibitors with better efficacy, and the present invention provides such compounds. Summary of the invention
[0004] Purpose of the invention: The purpose of the present invention is to provide a compound or a pharmaceutically acceptable salt thereof that can effectively inhibit the activity of NQO1; another purpose of the present invention is to provide a method for preparing the above-mentioned compound or a pharmaceutically acceptable salt thereof; another purpose of the present invention is to provide a pharmaceutical composition; another purpose of the present invention is to provide an application of a compound or a pharmaceutically acceptable salt thereof.
[0005] Technical solution: A compound represented by the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof,
[0006]
[0007] Among them, Ar 1 represents a 5- to 6-membered aromatic ring containing carbon atoms and / or nitrogen atoms;
[0008] Ar 2 Represents a benzene ring, triazole or a 5- to 6-membered aromatic heterocycle;
[0009] Ar 3 represents an aryl group containing 5 to 6 atoms, or an 8-10-membered bicyclic aryl or heteroaryl group, wherein the heteroaryl group is an aryl group containing 1 to 2 identical or different heteroatoms selected from nitrogen and oxygen in the aromatic ring members;
[0010] R 1 Represents a hydrogen atom or is located in Ar 1 One or more substituents at any position on the ring, the substituents being selected from C1-C4 alkyl, C1-C4 alkoxy, halogen, acyl, hydroxyl;
[0011] R 2 Represents absence, hydrogen atom, methylene, or in Ar 2 One or more substituents at any position on the ring, the substituents being selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 haloalkyl, halogen, trifluoromethoxy, cyano, hydroxyl, amino, carboxyl, and nitro;
[0012] R 3 Representatives are located in Ar 3 One or more substituents at any position on the ring, the substituents being selected from hydrogen, alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 haloalkyl, halogen, phenyl, trifluoromethoxy, cyano, hydroxyl, amino, carboxyl, sulfamoyl, C1-C4 alkylsulfonyl, C1-C4 acylamino, C1-C4 alkylaminoacyl;
[0013] When m is 0, X represents CH2; when m is 1, X represents O.
[0014] In the general formula (I), the dotted line represents the group Ar 3 and R 3 Preferably, the above compound or its pharmaceutically acceptable salt has a chemical structure as shown in (I-a) or (I-b):
[0015]
[0016] Among them, R 2 It means that Ar 2 and Ar 3 Direct connection, i.e.
[0017] Furthermore, Ar 1 Represents benzene ring, pyridine; Ar 2 represents a benzene ring, triazole or a 5-6 membered aromatic heterocycle containing 1-3 nitrogen atoms; Ar 3represents a benzene ring, a 5- to 6-membered aromatic heterocyclic ring, or an 8- to 10-membered bicyclic aromatic ring, wherein the 5- to 6-membered aromatic heterocyclic ring is an aromatic ring containing 1 to 2 identical or different heteroatoms selected from nitrogen and oxygen in the aromatic ring members
[0018] Preferably, the 8- to 10-membered bicyclic aromatic group is a condensed ring or biphenyl.
[0019] Furthermore, R 1 represents H, -CH3, -OCH3, -F, -OC(O)CH3, -OH;
[0020] R 2 Represents absence, -Cl, -F, trifluoromethoxy, nitro, -CH3, -CH2NH2, -OCF3, -COOH, -CN, methoxy, -OH, SO2CH3, -C(O)NH2, C(O)NHCH2CH3.
[0021] Further,
[0022] Ar 1 Selected from
[0023] Ar 2 Selected from Ar 3 Selected from
[0024] Further,
[0025] Ar 1 Selected from Ar 2 Selected from Ar 3 Selected from Typical compounds of the present invention include, but are not limited to:
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033] Preferably, the compound of formula (I) may contain an acidic functional group sufficient to form a salt. Representative salts include pharmaceutically acceptable metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum and zinc salts; pharmaceutically acceptable metal cations such as carbonates and bicarbonates of sodium, potassium, lithium, calcium, magnesium, aluminum and zinc; pharmaceutically acceptable organic primary, secondary and tertiary amines, including aliphatic amines, aromatic amines, aliphatic diamines and hydroxyalkylamines, such as methylamine, ethylamine, 2-hydroxyethylamine, diethylamine, triethylamine, ethylenediamine, ethanolamine, diethanolamine.
[0034] In another aspect, the present invention provides a method for preparing the above-mentioned compound or a pharmaceutically acceptable salt thereof.
[0035]
[0036] ;or,
[0037]
[0038]
[0039] Among them, R 1 , R 2 , R 3 ,Ar 1 ,Ar 2 ,Ar 3 , X and m are defined as above.
[0040] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
[0041] In another aspect, the present invention provides a use of the above-mentioned compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diseases related to abnormal NQO1 enzyme.
[0042] Preferably, the diseases associated with abnormal NQO1 enzyme include pancreatic cancer and non-small cell lung cancer.
[0043] In another aspect, the present invention provides a use of the above compound or a pharmaceutically acceptable salt thereof in the preparation of an NQO1 inhibitor.
[0044] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: 2-oxysubunit-1H-quinoline-4-carboxylic acid derivatives that can effectively inhibit the activity of NQO1 can be used in combination with anti-tumor drugs to treat pancreatic cancer and non-small cell lung cancer, while reducing the dosage of anti-tumor drugs, reducing side effects, and ensuring the safety of medication. DETAILED DESCRIPTION
[0045] Example 1: Preparation of Compound I-1:
[0046] Dissolve 7-fluoro-1H-indole-2,3-dione (330 mg, 2 mmol) in 20 mL of ethanol, then add ethyl diazoacetate (420 μL, 4 mmol) and DBU (60 μL, 0.3 mmol), and place the reaction solution at 40 ° C for 15 h. After the reaction is completed, spin dry the solvent, add 20 mL of 1N hydrochloric acid, and solid precipitates. Filter to obtain a light yellow solid (382 mg, 76%). Dissolve 8-fluoro-3-hydroxy-2-oxyylidene-1H-quinoline-4-carboxylic acid ethyl ester (200 mg, 0.8 mmol) in 15 mL of DMF, add benzyl bromide (110 μL, 0.96 mmol) and anhydrous potassium carbonate (220 mg, 1.6 mmol), and place the reaction solution at 66 ° C for 10 h. After the reaction, 20 mL of water and ethyl acetate were added for extraction, the organic phase was retained, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography with petroleum ether / ethyl acetate (6:1) to obtain a white solid (101 mg, 37.4%). 2-(Benzyloxy)-8-fluoro-2-oxyylidene-1H-quinoline-4-carboxylic acid ethyl ester (70 mg, 0.2 mmol) was dissolved in 10 mL (1:1) of a mixed solution of methanol and tetrahydrofuran, followed by addition of potassium hydroxide (460 mg, 8.2 mmol) and 5 mL of water, and the reaction solution was placed at 65 ° C for 18 h. After the reaction, the organic solvent was dried by spin drying, 1N hydrochloric acid was added to adjust the pH to 2, and a white solid precipitated, which was filtered and dried to obtain 56.3 mg of a white solid, with a total yield of 9.0%. 1 HNMR (400MHz, DMSO-d6) δ14.12(s,1H),12.35(s,1H),7.50-7.45(m,2H),7.44-7.37(m,3H),7.37-7.33(m,1H),7.26-7.20(m,2H),5.28(s,2H); EI-MS m / z:312.08[M] - .
[0047] Example 2: Preparation of Compound I-2:
[0048] The method of Example 2 was the same as that of Example 1, except that p-chlorobenzyl bromide (0.96 mmol) was used to replace benzyl bromide, to obtain 73.4 mg of a white solid with a total yield of 10.6%. 1 H NMR (400MHz, DMSO-d6) δ14.15(s,1H),12.36(s,1H),7.51-7.44(m,4H),7.44-7.38(m,1H),7.26-7.20(m,2H),5.27(s,2H); EI-MS m / z:346.01[M] - .
[0049] Example 3: Preparation of Compound I-3:
[0050] The method of Example 3 was the same as that of Example 1, except that p-fluorobenzyl bromide (0.96 mmol) was used to replace benzyl bromide to obtain 87.1 mg of a white solid with a total yield of 13.2%. 1 EI-MS m / z:330.14[M] - .
[0051] Example 4: Preparation of Compound I-4:
[0052] The method of Example 4 was the same as that of Example 1, except that 7-methoxy-1H-indole-2,3-dione (2 mmol) was used to replace 7-fluoro-1H-indole-2,3-dione to obtain 64.2 mg of a white solid with a total yield of 9.8%. 1 H NMR(400MHz,DMSO-d6)δ13.93(s,1H),11.39(s,1H),7.50-7.45(m,2H),7.42-7.31(m ,3H),7.23-7.12(m,2H),6.98(dd,J=7.9,1.3Hz,1H),5.26(s,2H),3.92(s,3H); EI-MS m / z:324.32[M] - .
[0053] Example 5: Preparation of Compound I-5:
[0054] The method of Example 5 is the same as that of Example 1, except that 7-methoxy-1H-indole-2,3-dione (2 mmol) is used to replace 7-fluoro-1H-indole-2,3-dione, and p-chlorobenzyl bromide (0.96 mmol) is used to replace benzyl bromide, to obtain 77.2 mg of a white solid with a total yield of 10.8%. 1 HNMR (400MHz, DMSO-d6) δ13.95(s,1H),11.41(s,1H),7.47(q,J=8.5Hz,4H),7.22-7.12(m,2H),6.98(d,J=7.8Hz,1H),5.25(s,2H),3.92(s,3H); EI-MS m / z:358.4[M] - .
[0055] Example 6: Preparation of Compound I-6:
[0056] The method of Example 6 was the same as that of Example 1, except that 7-methoxy-1H-indole-2,3-dione (2 mmol) was used to replace 7-fluoro-1H-indole-2,3-dione, and p-fluorobenzyl bromide (0.96 mmol) was used to replace benzyl bromide, to obtain 96.3 mg of a white solid with a total yield of 14.1%. 1 HNMR(400MHz,DMSO-d6)δ13.94(s,1H),11.41(s,1H),7.51(dd,J=8.5,5.8Hz, 2H),7.26-7.11(m,4H),6.98(d,J=8.0Hz,1H),5.24(s,2H),3.92(s,3H); EI-MS m / z:342.3[M] - .
[0057] Example 7: Preparation of Compound I-7:
[0058] The method of Example 7 was the same as that of Example 1, except that 7-hydroxy-1H-indole-2,3-dione (2 mmol) was used to replace 7-fluoro-1H-indole-2,3-dione to obtain 88.4 mg of a white solid with a total yield of 14.2%. 1 H NMR(300MHz,DMSO-d6)δ13.83(s,1H),11.15(s,1H),10.45(s,1H),7.48-7.35(m,5H), 7.06(t,J=7.9Hz,1H),6.93(d,J=6.6Hz,1H),6.85(d,J=8.0Hz,1H),5.24(s,2H); EI-MS m / z:310.3[M] - .
[0059] Example 8: Preparation of Compound I-8:
[0060] The method of Example 8 was the same as that of Example 1, except that 7-hydroxy-1H-indole-2,3-dione (2 mmol) was used to replace 7-fluoro-1H-indole-2,3-dione, and p-chlorobenzyl bromide (0.96 mmol) was used to replace benzyl bromide to obtain 78.2 mg of a white solid with a total yield of 11.3%. 1 HNMR(400MHz,DMSO-d6)δ13.89(s,1H),11.12(s,1H),10.43(s,1H),7.47(q,J=8.6Hz,4H),7.06 (t,J=7.9Hz,1H),6.94(d,J=6.7Hz,1H),6.85(d,J=7.3Hz,1H),5.24(s,2H);EI-MSm / z:344.8[M] - .
[0061] Example 9: Preparation of Compound I-9:
[0062] The method of Example 9 is the same as that of Example 1, except that 7-fluoro-1H-indole-2,3-dione (2 mmol) is substituted for 7-hydroxy-1H-indole-2,3-dione, and p-fluorobenzyl bromide (0.96 mmol) is substituted for benzyl bromide to obtain 69.3 mg of a white solid with a total yield of 10.5%. 1 HNMR(400MHz,DMSO-d6)δ13.86(s,1H),11.11(s,1H),10.42(s,1H),7.51(dd,J=8.5,5.8Hz,2H),7.21( t,J=8.9Hz,2H),7.06(t,J=7.9Hz,1H),6.93(d,J=7.9Hz,1H),6.85(d,J=8.0Hz,1H),5.23(s,2H); EI-MS m / z:328.3[M] - .
[0063] Example 10: Preparation of Compound I-10:
[0064] The method of Example 10 is the same as that of Example 1, except that 7-fluoro-1H-indole-2,3-dione (2 mmol) is substituted for 7-hydroxy-1H-indole-2,3-dione, and 4-trifluoromethylbenzyl bromide (0.96 mmol) is substituted for benzyl bromide to obtain 79.3 mg of a white solid with a total yield of 20.9%. 1 H NMR (400MHz, DMSO-d6) δ13.43(s,1H),10.34(d,J=5.2Hz,2H),7.70-7.63(m,2H),7.50(dt,J=7.1,1.0Hz,2H EI-MS m / z:378.3[M] - .
[0065] Example 11: Preparation of Compound I-11:
[0066] The method of Example 11 is the same as that of Example 1, except that 7-fluoro-1H-indole-2,3-dione (2 mmol) is used to replace 7-hydroxy-1H-indole-2,3-dione, and 1-(bromomethyl)-4-nitrobenzene (0.96 mmol) is used to replace benzyl bromide to obtain 88.5 mg of a white solid with a total yield of 12.9%. 1H NMR(400MHz,Chloroform-d)δ13.06(s,1H),9.84(s,1H),8.71(s,1H),8.14-8.07(m,2H),7.66-7.58(m,2H EI-MS m / z:355.1[M] - .
[0067] Example 12: Preparation of Compound I-12:
[0068] The method of Example 12 is the same as that of Example 1, except that 7-fluoro-1H-indole-2,3-dione (2 mmol) is substituted for 7-hydroxy-1H-indole-2,3-dione, and 4-methylbenzyl bromide (0.96 mmol) is substituted for benzyl bromide to obtain 76.3 mg of a white solid with a total yield of 11.7%. 1 HNMR(400MHz,DMSO-d6)δ13.43(s,1H),10.34(d,J=5.2Hz,2H),7.46(dd,J=8.1,1.2Hz,1H),7.31-7.21(m,1 EI-MS m / z:324.32[M] - .
[0069] Example 13: Preparation of Compound I-13:
[0070] The method of Example 13 is the same as that of Example 1, except that 7-hydroxy-1H-indole-2,3-dione (2 mmol) is used to replace 7-fluoro-1H-indole-2,3-dione, and [4-(bromomethyl)phenyl]methanamine (0.96 mmol) is used to replace benzyl bromide to obtain 99.3 mg of a white solid with a total yield of 14.6%. 1 H NMR(400MHz, DMSO-d6)δ13.43(s,1H),10.34(d,J=5.2Hz,2H),7.46(dd,J=8.1,1.2Hz,1H),7.36-7.22(m,5H), 6.94(dd,J=8.7,1.2Hz,1H),5.30(t,J=1.0Hz,2H),3.97(tt,J=6.2,1.0Hz,2H),3.45(d,J=12.6Hz,1H); EI-MS m / z:339.34[M]- .
[0071] Example 14: Preparation of Compound I-14:
[0072] The method of Example 14 is the same as that of Example 1, except that 7-hydroxy-1H-indole-2,3-dione (2 mmol) is used to replace 7-fluoro-1H-indole-2,3-dione, and 1-(bromomethyl)-3-[(trifluoromethyl)oxy]benzene (0.96 mmol) is used to replace benzyl bromide to obtain 99.9 mg of a white solid with a total yield of 12.6%. 1 H NMR (400MHz, DMSO-d6) δ13.43(s,1H),10.34(d,J=5.2Hz,2H),7.46(dd,J=8.1,1.2Hz,1H),7.31-7.22( EI-MS m / z:394.35[M] - .
[0073] Example 15: Preparation of Compound I-15:
[0074] The method of Example 15 is the same as that of Example 1, except that 7-fluoro-1H-indole-2,3-dione (2 mmol) is substituted for 7-hydroxy-1H-indole-2,3-dione, and 5-(bromomethyl)pyridine-2-carboxylic acid (0.96 mmol) is substituted for benzyl bromide to obtain 82.3 mg of a white solid with a total yield of 11.5%. 1 H NMR (400MHz, DMSO-d6) δ13.43(s,1H),12.82(s,1H),10.34(d,J=5.2Hz,2H),8.59(d,J=2.2Hz,1H),8.06(d,J=8.1Hz,1H),7 .69(dd,J=8.1,2.3Hz,1H),7.46(dd,J=8.1,1.2Hz,1H),7.31-7.22(m,1H),6.94(dd,J=8.7,1.2Hz,1H),5.46(s,1H); EI-MS m / z:355.29[M] - .
[0075] Example 16: Preparation of Compound I-16:
[0076] The method of Example 16 is the same as that of Example 1, except that 6-methyl-1H-pyrrolo[2,3-b]pyridine-2,3-dione (2 mmol) is used to replace 7-fluoro-1H-indole-2,3-dione, and 4-(bromomethyl)aniline (0.96 mmol) is used to replace benzyl bromide to obtain 82.3 mg of a white solid with a total yield of 11.5%. 1H NMR(400MHz,Chloroform-d)δ13.12(s,1H),9.87(s,1H),7.85(d,J=8.2Hz,1H),7.32-7.23(m,2H),7.17- 7.10(m,1H),6.61-6.54(m,2H),5.30(t,J=0.9Hz,2H),4.17(d,J=5.7Hz,1H),4.07(d,J=5.7Hz,1H); EI-MS m / z:324.11[M] - .
[0077] Example 17: Preparation of Compound I-17:
[0078] 7-Hydroxy-1H-indole-2,3-dione (326 mg, 2 mmol) was dissolved in 10 mL DMF, the reaction solution was placed in an ice bath at 0°C, then NaH (48 mg, 2 mmol) was added, stirred for 10 min, and then acetic anhydride (281 μL, 3 mmol) was added and reacted for 2 h. After the reaction was completed, 20 mL of water was added to quench the reaction, and ethyl acetate (10 mL × 3) was used for extraction. The organic phase was retained and dried over anhydrous sodium sulfate. The product was purified by silica gel column chromatography with petroleum ether / ethyl acetate (5:1) to obtain a yellow solid (390 mg, 95.1%), namely acetic acid-2,3-dioxy-2,3-dihydro-1H-indol-7-yl ester. The method of Example 17 is the same as that of Example 1, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (2 mmol) is used to replace 7-fluoro-1H-indole-2,3-dione, and 4-(bromomethyl)benzene-1-carbonitrile (0.96 mmol) is used to replace benzyl bromide to obtain 105.3 mg of a white solid with a total yield of 13.9%. 1 H NMR(400MHz,DMSO-d6)δ13.27(s,1H),10.54(s,1H),7.70-7.63(m,2H),7.53-7.46( m,2H),7.46-7.38(m,2H),7.21(dd,J=6.0,4.2Hz,1H),5.30(t,J=1.0Hz,2H); EI-MS m / z:377.34[M] - .
[0079] Example 18: Preparation of Compound I-18:
[0080] The method of Example 18 is the same as that of Example 1, except that 7-fluoro-1H-indole-2,3-dione (2 mmol) is substituted for 7-hydroxy-1H-indole-2,3-dione, and 4-methoxybenzyl bromide (0.96 mmol) is substituted for benzyl bromide to obtain 97.3 mg of a white solid with a total yield of 14.2%. 1 H NMR(400MHz,Chloroform-d)δ13.06(s,1H),9.84(s,1H),8.71(s,1H),7.45(dd,J=8.2,1.3Hz,1H), 7.38-7.30(m,2H),7.30-7.22(m,1H),6.98-6.88(m,3H),5.30(t,J=1.0Hz,2H),3.78(s,3H); EI-MS m / z:340.3[M] - .
[0081] Example 19: Preparation of Compound I-19:
[0082] 1-(Azidomethyl)-4-fluorobenzene (1g, 5mmol) was dissolved in 5mL of anhydrous DMF, followed by the addition of pent-4-ynoic acid (490mg, 5mmol), copper sulfate pentahydrate (62.5mg, 0.25mmol) and sodium ascorbate (49.5mg, 0.25mmol), and the reaction solution was placed at 80°C for 15h. The reaction was terminated, cooled to room temperature, and water and ethyl acetate were added for extraction. The organic phase was retained, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography with petroleum ether / ethyl acetate (1:1) to obtain a white solid (1.3g, 87.6%). 3-{1-[(4-fluorophenyl)methyl]-1,2,3-triazacyclopentyl-4-yl}propanoic acid (460 mg, 1.85 mmol) was placed in a 50 mL reaction bottle, 3 mL of thionyl chloride was slowly added dropwise, stirred at room temperature for 2 h, and then thionyl chloride was removed by rotary evaporation to obtain a light yellow oil (0.49 g, 98.9%). 7-Methoxy-1H-indole-2,3-dione (177 mg, 1 mmol) was dissolved in 10 mL of dichloromethane, followed by the addition of pyridine (320 mL, 4 mmol), and the dichloromethane solution of 3-{1-[(4-fluorophenyl)methyl]-1,2,3-triazacyclopentane-4-yl}propanoyl chloride (350 mg, 1.33 mmol) was added dropwise in 5 mL. After the addition was complete, the reaction solution was placed at 50 ° C for 12 h, the reaction was terminated, cooled to room temperature, washed with 1N hydrochloric acid, extracted three times with dichloromethane, the organic phase was retained, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography with dichloromethane / methanol (50:1) to obtain a brown solid (110 mg, 31.2%). 1-(3-{1-[(4-fluorophenyl)methyl]-1,2,3-triazacyclopentyl-4-yl}propanoyl)-7-methoxyindole-2,3-dione (180 mg, 0.43 mmol) was dissolved in 15 mL (2:1) of a mixed solution of methanol and water, followed by the addition of sodium hydroxide (185 mg, 4.3 mmol). The reaction solution was placed at 105°C for 12 h. After the reaction was completed, it was cooled to room temperature, the methanol was removed by rotation, and 1N hydrochloric acid was added to adjust the pH to 2. A white solid precipitated, which was filtered and dried to obtain 150 mg of a white solid with a total yield of 36.7%. 1 H NMR(300MHz,DMSO-d6)δ14.14(s,1H),11.20(s,1H),7.76(s,1H),7.36-7.31(m,2H ),7.21-7.14(m,4H),7.08-7.02(m,1H),5.49(s,2H),3.91(d,J=1.8Hz,5H); EI-MS m / z:407.1[M] - .
[0083] Example 20: Preparation of Compound I-20:
[0084] The method of Example 20 was the same as that of Example 19, except that 1-(azidomethyl)-4-(trifluoromethyl)benzene (5 mmol) was used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 110.3 mg of a white solid with a total yield of 24.1%. 1 H NMR (400MHz, DMSO-d6) δ14.18(s,1H),11.18(s,1H),7.83(s,1H),7.72(d,J=8.0Hz,2H),7.44(d,J=8.0Hz, 2H),7.19(d,J=5.3Hz,2H),7.05(p,J=4.2Hz,1H),5.63(s,2H),3.92(d,J=6.4Hz,5H);EI-MSm / z:457.1[M] - .
[0085] Example 21: Preparation of Compound I-21:
[0086] The method of Example 21 was the same as that of Example 19, except that 7-methoxy-1H-indole-2,3-dione was replaced with 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) to obtain 99.7 mg of a yellow solid with a total yield of 25.3%. 1 H NMR (400MHz, DMSO-d6) δ13.80(s,1H),10.88(s,1H),10.42(s,1H),7.76(s,1H),7.34(dd,J=8.5,5.6Hz,2H),7.18(t ,J=8.8Hz,2H),7.05(d,J=7.9Hz,1H),6.98(d,J=7.9Hz,1H),6.92(d,J=8.0Hz,1H),5.49(s,2H),3.89(s,2H); EI-MS m / z:393.11[M] - .
[0087] Example 22: Preparation of Compound I-22:
[0088] The method of Example 22 is the same as that of Example 19, except that 7-methoxy-1H-indole-2,3-dione is replaced by 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol), and 1-(azidomethyl)-4-(trifluoromethyl)benzene (5 mmol) is replaced by 1-(azidomethyl)-4-fluorobenzene to obtain 80.2 mg of a yellow solid with a total yield of 18.3%. 1H NMR (400MHz, DMSO-d6) δ10.90(s,1H),10.55(s,1H),7.84(s,1H),7.72(d,J=8.3Hz,2H),7.44(d ,J=8.2Hz,2H),7.08-7.01(m,2H),6.91(dd,J=7.3,1.9Hz,1H),5.64(s,2H),3.91(s,2H); EI-MS m / z:443.11[M] - .
[0089] Example 23: Preparation of Compound I-23:
[0090] The method of Example 23 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 4-(azidomethyl)-1-methylbenzene (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 79.3 mg of a yellow solid with a total yield of 20.1%. 1 H NMR (400MHz, DMSO-d6) δ12.75(s,1H),10.83(s,1H),10.22(s,1H),7.92(s,1H),7.64(dd,J=8.2,1.1Hz,1H),7.31(t,J=8.5Hz,1H EI-MS m / z:389.4[M] - .
[0091] Example 24: Preparation of Compound I-24:
[0092] The method of Example 24 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 4-(azidomethyl)-1-methoxybenzene (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 89.1 mg of a yellow solid with a total yield of 21.9%. 1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H),7.62(dd,J=8.1,1.2Hz,1H),7.36-7.27(m ,1H),7.26-7.18(m,2H),6.99(dd,J=8.8,1.1Hz,1H),6.86-6.79(m,2H),5.32(t,J=1.0Hz,2H),4.03(s,2H),3.78(s,3H); EI-MS m / z:405.4[M] - .
[0093] Example 25: Preparation of Compound I-25:
[0094] The method of Example 25 is the same as that of Example 19, except that 7-methoxy-1H-indole-2,3-dione is replaced by 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol), and 1-(azidomethyl)-4-fluorobenzene is replaced by [4-(azidomethyl)phenyl]methaneamine (5 mmol) to obtain 95.4 mg of a yellow solid with a total yield of 23.5%. 1 H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H ),7.62(dd,J=8.1,1.2Hz,1H),7.40-7.32(m,2H),7.30(d,J=8.5Hz,1H),7.24-7.1 6(m,2H),6.99(dd,J=8.8,1.1Hz,1H),5.31(t,J=1.0Hz,2H),4.03(s,2H),3.95(tt ,J=6.2,1.0Hz,2H),2.76(dt,J=7.1,6.3Hz,1H),2.54(dt,J=7.1,6.3Hz,1H); EI-MS m / z:404.14[M] - .
[0095] Example 26: Preparation of Compound I-26:
[0096] The method of Example 26 is the same as that of Example 19, except that 7-methoxy-1H-indole-2,3-dione is replaced by 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol), and 1-(azidomethyl)-4-fluorobenzene is replaced by 4-(azidomethyl)-1-phenylbenzene (5 mmol) to obtain 100.3 mg of a yellow solid with a total yield of 22.2%. 1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H),7.65-7.55( EI-MS m / z:451.47[M] - .
[0097] Example 27: Preparation of Compound I-27:
[0098] The method of Example 27 is the same as that of Example 19, except that 7-methoxy-1H-indole-2,3-dione is replaced by 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol), and 1-(azidomethyl)-4-fluorobenzene is replaced by 4-(azidomethyl)-1-[(trifluoromethyl)oxy]benzene (5 mmol) to give 110.3 mg of a yellow solid with a total yield of 23.9%. 1 H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H),7.62(dd,J=8.1,1.2Hz,1H),7.36- 7.26(m,2H),7.25(d,J=0.9Hz,1H),7.24-7.16(m,2H),6.99(dd,J=8.8,1.1Hz,1H),5.32(t,J=0.9Hz,2H),4.03(s,2H).
[0099] EI-MS m / z:459.37[M] -
[0100] Example 28: Preparation of Compound I-28:
[0101] The method of Example 28 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 4-(azidomethyl)benzene-1-carbonitrile (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 99.9 mg of a yellow solid with a total yield of 24.9%. 1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H),7.62(dd,J=8.1,1.2Hz,1H), 7.59-7.46(m,4H),7.31(d,J=17.0Hz,1H),6.99(dd,J=8.8,1.1Hz,1H),5.32(t,J=1.0Hz,2H),4.03(s,2H); EI-MS m / z:400.28[M] - .
[0102] Example 29: Preparation of Compound I-29:
[0103] The method of Example 29 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 4-(azidomethyl)phenol (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 87.5 mg of a yellow solid with a total yield of 22.3%. 1 H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H),7.62(dd,J=8.1,1.2Hz,1H EI-MS m / z:391.37[M] - .
[0104] Example 30: Preparation of Compound I-30:
[0105] The method of Example 30 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 4-(azidomethyl)aniline (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 84.2 mg of a yellow solid with a total yield of 21.5%. 1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H),7.62(dd,J=8.1,1.2Hz,1H),7.35(q,J=1.2Hz,1H), 7.34-7.27(m,2H),6.99(dd,J=8.8,1.1Hz,1H),6.56-6.48(m,2H),5.32(t,J=1.0Hz,2H),4.17(d,J=5.7Hz,1H),4.10-4.01(m,3H); EI-MS m / z:390.39[M] - .
[0106] Example 31: Preparation of Compound I-31:
[0107] The method of Example 31 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 4-(azidomethyl)benzoic acid (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 107.2 mg of a yellow solid with a total yield of 25.5%. 1 H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),8.12(s,1H),7.92-7.84(m,2H),7.79(s,1H),7.62(dd, EI-MS m / z:419.38[M] - .
[0108] Example 32: Preparation of Compound I-32:
[0109] The method of Example 32 is the same as that of Example 19, except that 7-methoxy-1H-indole-2,3-dione is replaced by 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol), and 1-(azidomethyl)-4-fluorobenzene is replaced by 4-(azidomethyl)benzene-1-sulfonamide (5 mmol) to obtain 96.3 mg of a yellow solid with a total yield of 21.1%. 1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(dd,J=7.0,1.7Hz,3H),7.62(dd,J=8.1,1.2Hz,1H EI-MS m / z:454.45[M] - .
[0110] Example 33: Preparation of Compound I-33:
[0111] The method of Example 33 was the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) was used to replace 7-methoxy-1H-indole-2,3-dione, and [4-(azidomethyl)phenyl](methyl)dioxy-λ 6 -sulfane (5 mmol) was used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 98.8 mg of a yellow solid with an overall yield of 21.8%. 1 H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.79(s,1H),7.76-7.69(m,2H),7.62(dd,J=8.1,1.2Hz,1 EI-MS m / z:453.46[M] - .
[0112] Example 34: Preparation of Compound I-34:
[0113] The method of Example 34 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 4-(azidomethyl)benzene-1-carboxamide (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 81.9 mg of a yellow solid with a total yield of 19.5%. 1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),7.92-7.84(m,2H),7.79(s,1H),7.62(dd,J=8.1,1.2Hz,1H),7.48-7.40 EI-MS m / z:418.4[M] - .
[0114] Example 35: Preparation of Compound I-35:
[0115] The method of Example 35 is the same as that of Example 19, except that 7-methoxy-1H-indole-2,3-dione is replaced by 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol), and 1-(azidomethyl)-4-fluorobenzene is replaced by 4-(azidomethyl)-N-ethylbenzamide (5 mmol) to obtain 99.4 mg of a yellow solid with a total yield of 22.2%. 1 H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.89(s,1H),8.01(t,J=4.2Hz,1H),7.86-7.77(m,3H),7.62(dd,J=8.1,1.2Hz,1H),7.46-7 .38(m,2H),7.36-7.27(m,1H),6.99(dd,J=8.8,1.1Hz,1H),5.32(t,J=1.0 Hz, 2H), 4.03 (s, 2H), 3.40 (qd, J=6.3, 4.2Hz, 2H), 1.30-1.22 (m, 3H); EI-MS m / z:446.45[M] - .
[0116] Example 36: Preparation of Compound I-36:
[0117] The method of Example 36 is the same as that of Example 19, except that 2,3-dioxy-2,3-dihydro-1H-indol-7-yl acetate (1 mmol) is used to replace 7-methoxy-1H-indole-2,3-dione, and 7-(azidomethyl)quinoline (5 mmol) is used to replace 1-(azidomethyl)-4-fluorobenzene to obtain 89.5 mg of a yellow solid with a total yield of 20.9%. 1H NMR(400MHz,Chloroform-d)δ12.61(s,1H),10.00(s,1H),8.91-8.83(m,2H),8.18-8.12(m,1H),8.08(d,J=1.7Hz,1H),7.94(d,J=7.7Hz,1H) ,7.79(s,1H),7.62(dd,J=8.1,1.2Hz,1H),7.54-7.44(m,2H),7.36-7.27(m,1H),6.99(dd,J=8.8,1.1Hz,1H),5.41(s,2H),4.03(s,2H); EI-MS m / z:426.42[M] - .
[0118] Application Examples Partial pharmacological experiments and results of the present invention
[0119] The following are some pharmacological experiments and results of the compounds described in the present invention:
[0120] The NAD(P)H light absorption endpoint method was used to determine the activity of NQO1 inhibitors. The experimental equipment was a 96-well plate, and 2 μL (1 mM) of the test compound, 2 μL of human recombinant NQO1 protein, and 190 μL of PBS buffer solution (50 mM, pH = 7.4) were added to each well. After incubation at 37 ° C for 5 minutes, 4 μL of NADPH (20 mM) was added to each well, and then the 340 nm OD value was immediately detected using a SpectraMax i3x multi-function microplate reader. The test lasted for 5 minutes, with detection every 2 seconds, and the results were analyzed and calculated using Graphpad Prism 8. The blank control sample used in the test contained 192 μL of buffer solution and 2 μL of NQO1 protein, and 4 μL of NADPH was added after incubation for testing; the positive control sample contained 190 μL of buffer solution, 2 μL of NQO1 protein, and 2 μL of DIC, and 4 μL of NADPH was added after incubation for testing. The buffer solution contains 0.2M Na2HPO4, 0.2M NaH2PO4, and 0.9% NaCl. The test results of representative compounds are shown in Table 1. Where A represents the IC value for NQO1 50 The value is less than 0.5 μM, B indicates the IC of NQO1 50 The values range from 0.5 μM to 1 μM, and C represents the IC of NQO1. 50 The values range from 1 μM to 10 μM. D represents the IC of NQO1. 50 Values range from 10 μM to 15 μM.
[0121] Table 1 Activity of the compounds of the present invention
[0122]
[0123]
[0124] As shown in Table 1, the 2-oxy-1H-quinoline-4-carboxylic acid compounds of the present invention have strong NQO1 enzyme inhibitory activity. Among the example compounds, the NQO1 protein inhibitory activity of the example-22 compound is the best.
[0125] In addition, seven compounds with inhibitory effect A were selected for combined use with antitumor drugs LDH inhibitor GNE-140 and gemcitabine for cytotoxicity to Mia PaCa-2 cells. Mia Paca-2 cells were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum. The growth inhibitory activity of the compounds on tumor cells was determined by MTT colorimetric assay. Different tumor cells were inoculated in 96-well plates and then placed in an incubator to wait for the cells to adhere. The cells were inoculated into 96-well microtiter plates at a density of 10,000 cells / mL and incubated at 37°C for 16 hours in a humid atmosphere of 5% carbon dioxide. All compounds were configured into 100mM mother solutions, and after the compounds were diluted to 200μM with buffer solution, they were diluted three times continuously to obtain the required concentration solution to be tested. Take 100μL of compound solution and 100μL of buffer solution and add them to each well of the 96-well plate. The 96-well plate was incubated at 37°C for 72 hours, and then 20 μL of 5 mg / mL MTT solution was added to each well and incubated in an incubator for 4 hours. After the incubation, the solution in each well was aspirated and removed, and 150 μL of DMSO solution was added to each well, and the well was shaken on a shaker for 10 minutes, and the OD value at 570 nm was detected. The test results are shown in Tables 2 and 3.
[0126] Table 2 Results of combined use of some compounds of the present invention and GNE-140
[0127]
[0128]
[0129] As shown in Table 2, the experimental results of the combined use of representative compounds of the present invention show that the representative compounds can enhance the efficacy of killing cancer cells when used in combination with GNE-140, and the two have a synergistic effect.
[0130] Table 3 Results of combined use of some compounds of the present invention with gemcitabine
[0131]
[0132] As shown in Table 3, the experimental results of the combined use of the representative compounds of the present invention show that the representative compounds can enhance the efficacy of killing cancer cells when used in combination with gemcitabine, and the two have a synergistic effect.
Claims
1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, characterized in that: Among them, Ar 1 represents a 5- to 6-membered aromatic ring containing carbon atoms and / or nitrogen atoms; Ar 2 represents a benzene ring, triazole or a 5- to 6-membered aromatic heterocycle; Ar 3 represents an aryl group containing 5 to 6 atoms, or an 8-10 membered bicyclic aryl or heteroaryl group, wherein the heteroaryl group is an aryl group containing 1 to 2 identical or different heteroatoms selected from nitrogen and oxygen in the aromatic ring members; R 1 Represents a hydrogen atom or is located in Ar 1 One or more substituents at any position on the ring, the substituents being selected from C1-C4 alkyl, C1-C4 alkoxy, halogen, acyl, and hydroxyl; R 2 Represents absence, hydrogen atom, methylene, or at Ar 2 One or more substituents at any position on the ring, the substituents being selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 haloalkyl, halogen, trifluoromethoxy, cyano, hydroxy, amino, carboxyl, and nitro; R 3 Representatives are located in Ar 3 One or more substituents at any position on the ring, the substituents being selected from hydrogen, alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 haloalkyl, halogen, phenyl, trifluoromethoxy, cyano, hydroxy, amino, carboxyl, sulfamoyl, C1-C4 alkylsulfonyl, C1-C4 acylamino, and C1-C4 alkylaminoacyl; When m is 0, X represents CH2; when m is 1, X represents O.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that Ar 1 Represents benzene ring, pyridine; Ar 2 represents a benzene ring, triazole or a 5- to 6-membered aromatic heterocycle containing 1-3 nitrogen atoms; Ar 3 It represents a benzene ring, a 5- to 6-membered aromatic heterocycle, or an 8- to 10-membered bicyclic aromatic group, wherein the 5- to 6-membered aromatic heterocycle is an aromatic group containing 1 to 2 identical or different heteroatoms selected from nitrogen and oxygen in the aromatic ring members.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that R 1 represents H, -CH3, -OCH3, -F, -OC(O)CH3, -OH; R 2 Represents absence, -Cl, -F, trifluoromethoxy, nitro, -CH3, -CH2NH2, -OCF3, -COOH, -CN, methoxy, -OH, SO2CH3, -C(O)NH2, C(O)NHCH2CH3.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that Ar 1 Selected from Ar 2 Selected from Ar 3 Selected from 5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that Ar 1 Selected from Ar 2 Selected from Ar 3 Selected from 6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that Select from any of the following chemical structures:
7. A method for preparing the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, characterized in that: or, Among them, R 1 、R 2 、R 3 、Ar 1 、Ar 2 、Ar 3 , X and m are defined as described in any one of claims 1-6.
8. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
9. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating diseases related to abnormalities in the NQO1 enzyme.
10. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof in the preparation of an NQO1 inhibitor.
Citation Information
Patent Citations
3-(1, 2, 3-triazole-4-yl) tetrahydroquinazoline-2, 4-diketone derivative as well as preparation method and application thereof
CN115974847A
Indole derivatives and methods of using the same
US20090227652A1
Substituted quinoline derivatives with antiviral action
US6114349A
